Analgesic Efficacy of Intravenous Lidocaine and/or Ketamine

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Postoperative Pain
Interventions
DRUG

Lidocaine,

Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.

DRUG

Ketamine

Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.

DRUG

association ketamine-lidocaine

Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.

DRUG

Placebo

The control group (C) received an equal volume of saline 0.9 % during 48 h.

Trial Locations (1)

CH-1011

University Hospital Center and University, Lausanne

All Listed Sponsors
lead

University of Lausanne Hospitals

OTHER

NCT01439399 - Analgesic Efficacy of Intravenous Lidocaine and/or Ketamine | Biotech Hunter | Biotech Hunter